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Abstract
The study of change in intermediate phenotypes over time is important in genetics. In this paper
we explore a new approach to phenotype definition in the genetic analysis of longitudinal
phenotypes. We utilized data from the longitudinal Framingham Heart Study Family Cohort to
investigate the familial aggregation and evidence for linkage to change in systolic blood pressure
(SBP) over time. We used Gibbs sampling to derive sigma-squared-A-random-effects (SSARs) for
the longitudinal phenotype, and then used these as a new phenotype in subsequent genome-wide
linkage analyses.
Additive genetic effects (σ2
A.time) were estimated to account for ~9.2% of the variance in the rate
of change of SBP with age, while additive genetic effects (σ2
A) were estimated to account for
~43.9% of the variance in SBP at the mean age. The linkage results suggested that one or more
major loci regulating change in SBP over time may localize to chromosomes 2, 3, 4, 6, 10, 11, 17,
and 19. The results also suggested that one or more major loci regulating level of SBP may localize
to chromosomes 3, 8, and 14.
Our results support a genetic component to both SBP and change in SBP with age, and are
consistent with a complex, multifactorial susceptibility to the development of hypertension. The
use of SSARs derived from quantitative traits as input to a conventional linkage analysis appears to
be valuable in the linkage analysis of genetically complex traits. We have now demonstrated in this
paper the use of SSARs in the context of longitudinal family data.
Background
The choice of phenotype is critical for the success of gene
discovery in complex human diseases. In the case of most
common, complex diseases, however, the choice is far
from simple. Diseases such as cardiovascular disease are
characterized by heterogeneity and are associated with a
large number of intermediate phenotypes, which are
themselves under complex genetic control and which may
change markedly over time. The study of change in these
intermediate phenotypes over time is important, as genes
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for disease severity or effect modification may be as or
more important than genes encoding disease risk per se.
In this paper we explore a new approach to phenotype
definition in the genetic analysis of longitudinal pheno-
types. The generalized linear mixed model (GLMM) [1]
provides the unifying framework and Gibbs sampling
[2,3] a means of fitting these models.
We utilized data from the longitudinal Framingham Heart
Study Family Cohort to investigate the familial aggrega-
tion and evidence for linkage to change in systolic blood
pressure (SBP) over time. Our primary aim was to assess
evidence for genetic effects on the rate of increase of SBP
with age, as well as genetic effects on SBP at any given
time. Our secondary aim was to derive sigma-squared-A-
random-effects (SSARs) for the longitudinal phenotype,
and to use these as a new phenotype in subsequent
genome-wide linkage analyses.
Methods
Data
We analyzed the longitudinal Framingham Heart Study
Family Cohort data set, provided for the Genetic Analysis
Workshop, which included 4692 individuals in all 330
pedigrees. The primary response variable of the GLMMs
and linkage models reported in this paper was the SBP
measured over time. Explanatory covariates for all models
included: sex, age, height, weight, number of drinks per
week, number of cigarettes per day. Sex (m = 1, f = 0) was
analyzed as a binary covariate. Other variables were
treated as continuous. All continuous covariates were cen-
tered at or close to their mean. In order to allow for a non-
linear increase in SBP with age, quadratic and cubic age
terms were also included. Although the model is Bayesian,
the effects of each covariate on the phenotype can also be
assessed using a pseudo-likelihood approach.
The covariates drink (number of drinks per week) and
CPD (number of cigarettes per day) were only measured
at 11 and 18 time points, respectively, in the first cohort.
However, the majority of individuals had only one or two
distinct values for these covariates throughout the study,
so each missing value of drink and CPD was replaced with
the mean of the covariates for that individual in the two
observations surrounding the missing observation. This
enabled us to increase the amount of useful observations
without excluding important covariates from the model.
The phenotypic component of the model included 24,746
observations for 2860 individuals. These observations all
had non-missing values for SBP, height, weight, age,
drink, and CPD.
Variance components model
The models fitted in this analysis are extensions of our
previously described variance components models for
extended pedigrees with normal, binary, or censored sur-
vival phenotypes [4,5]. The original models are GLMMs
with components of variance due to additive polygenic
effects (σ2
A), common family environment (σ2
C), and
common sibling environment (σ2
Cs), and since the phe-
notype in this analysis is assumed normally distributed,
an error variance (σ2
E). The complex familial correlation
structure is modeled through the use of shared random
effects for each variance component. The model for the jth
individual in the ith pedigree can be represented as:
µij = β0 + βTXij + Aij + Cij + Csij
yij ~ N(µij, σ2
E),
where yij is the observed phenotype, Xij is a matrix of cov-
ariates, Aij ~ N(0, VA), Cij ~ N(0, VC), Csij ~ N(0, VCs) and
the random effects are sampled from appropriate multi-
variate normal distributions with variance-covariance
matrices (VA, VC, and VCs) parameterized by σ2
A, σ2
C, and
σ2
Cs, respectively, and structured as described in [5]. Indi-
viduals without phenotypic data are used in generating
the random effects but not in the main model.
The extensions not only allow for repeated measures on
individuals, but also use the extra information available
to assess evidence for genetic effects on the rate of change
of the outcome over time [6]. At the kth observation for the
jth  individual in the ith  pedigree, the model can be
expressed as:
µijk = β0 + βTXijk + Aij + Cij + Csij + ageijk × (βage + A.timeij +
C.timeij + Cs.timeij + E.timeij)
yijk ~ N(µijk, σ2
E),
where yijk is the observed phenotype, Xijk is a matrix of cov-
ariates, βage is the mean gradient of age (for all individu-
als), Aij ~ N(0, σ2
A), Cij ~ N(0, σ2
C), Csij ~ N(0, σ2
Cs),
A.timeij ~ N(0, σ2
A.time), C.timeij ~ N(0, σ2
C.time), Cs.timeij
~ N(0, σ2
Cs.time), E.timeij ~ N(0, σ2
E.time).
In this model time was measured using the covariate age.
The random effects for the gradient of age, A.timeij,
C.timeij, Cs.timeij, and E.timeij, have a covariance struc-
ture equivalent to that described previously [5], with each
variance component replaced by its counterpart for the
gradient, so (for example) in this part of the model σ2
A is
represented by σ2
A.time. However, the variance compo-
nents for the intercepts (σ2
A, σ2
C, σ2
Cs, and σ2
E) are inde-
pendent of the variance components for the
corresponding gradients (σ2
A.time,  σ2
C.time,  σ2
Cs.time, andBMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/s1/S12
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σ2
E.time), and the estimated random effects for each vari-
ance component for the intercept are different from the
estimated random effects for each variance component for
the gradient. All random effects are constant across obser-
vations on the same individual; they do not change over
time. Just as the size of σ2
A can indicate whether additive
genetic effects influence the outcome, the size of σ2
A.time
can indicate whether additive genetic effects influence the
rate of change of the outcome with time. The narrow-
sense heritability (h2
N) was defined as the ratio of variance
due to additive genetic effects (σ2
A or σ2
A.time) to the total
phenotypic variance in SBP or rate of change in SBP [7].
The models were fitted using Gibbs sampling in Win-
BUGS v1.3 [8]. Because WinBUGS uses a Bayesian formu-
lation, prior distributions must be specified for all
parameters of interest. Vague normal N(0, 1000) priors
were specified for fixed regression coefficients. Vague
Pareto(1, 0.001) priors were specified on the precisions
(inverses of the variances) of all random effects; these
were equivalent to specifying uniform priors on the corre-
sponding variances. Models were run for 45,000 iterations
after a burn-in of 5000 iterations.
Blood pressure adjustment
The problem of how to model continuous SBP when
some individuals are on blood pressure treatment is com-
plex. However, since complex modelling of SBP was not
the main aim of this particular analysis, we chose a simple
method of adjustment based on known average treatment
effects [9,10]. This involved adding a constant (10 mm
Hg) to each phenotype where the individual was on treat-
ment, to reflect the 'true' SBP that might have been
observed if the individual had not been on treatment.
Linkage analysis
As described previously, the random effects due to σ2
A (Aij,
the sigma-squared A residuals, or SSARs) can be used as a
continuous phenotype in a linkage analysis [11,12]. The
SSARs for the gradient (A.timeij, the sigma-squared A time
residuals or SSATRs), may also be used in such a way. The
estimated SSARs and SSATRs were used as continuous
phenotypes in a multipoint variance components linkage
analysis that was performed using SOLAR v1.7.4 [13]. All
395 markers were included. The most common approach
undertaken in previous genetic analyses of longitudinal
data has been to estimate a simple linear gradient in each
subject and then use this as a phenotype. Therefore, in
order to compare our SSAR methodology to such an
approach, we also estimated a simple linear gradient in
each subject and used this as an outcome into the SOLAR
linkage analyses.
Results
Results from fitting the variance components model in
WinBUGS are shown in Table 1. Both means ('best esti-
mates') and 95% credible intervals are presented for each
parameter. We deliberately excluded certain intermediate
phenotypes (such as cholesterol and BMI) from the model
even though they were clearly related to SBP, because we
did not want to model away their contribution to
variation in SBP.
The size of σ2
A.time (relative to the other variance compo-
nents for the gradient) gave a h2
N estimate of ~9.2%, sug-
gesting that genes do influence the rate of change of SBP
with age, but that nongenetic influences due to shared
familial or sibling environment are more important. In
contrast, the variance components estimates for the inter-
cept suggest that additive genetic effects are the largest
component of variance for SBP at the mean age (h2
N ~
43.9%).
The mean rate of change of SBP with each year was 0.62,
suggesting that for the average individual, SBP increases
by approximately 6.2 mm Hg every 10 years. A nonlinear
effect was also apparent, since the credible intervals for
both the quadratic and cubic terms excluded 0 (Figure 1).
Other covariates also appeared to influence SBP. Males
tended to have lower SBP than females, and individuals
from the second cohort tended to have lower SBP than
those included in the first cohort. Both increasing weight
Modeled age-related change in SBP over time (model  adjusted for treatment, weight, drink, sex and cohort  membership) Figure 1
Modeled age-related change in SBP over time (model 
adjusted for treatment, weight, drink, sex and cohort 
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and number of drinks consumed per day was significantly
associated with increased SBP. Height and number of cig-
arettes per day appeared to show little association with
SBP.
Results changed little when σ2
E.time was excluded, when
σ2
C and  σ2
C.time were excluded, when σ2
Cs and  σ2
Cs.time
were excluded, and when the SBP adjustment (for those
on blood pressure treatment) was changed to +5 mm Hg
or +20 mm Hg (instead of +10 mm Hg). A number of
Table 1: Results from main model
Parameter Mean 95% Credible Interval
Fixed effects
β0 136.8 157.5 to 174.4
β.age 0.618 0.581 to 0.656
β.age2A 0.014 0.013 to 0.015
β.age3B -1.884 × 10-4 -2.285 × 10-4 to -1.493 × 10-4
β.cohort -9.947 -11.02 to -8.916
β.male -4.488 -5.597 to -3.375
β.wgt 0.516 0.485 to 0.547
β.wgt2C -0.002 -0.003 to -0.001
β.hgt -1.956 -8.216 to 4.211
β.drink 0.0453 0.034 to 0.057
β.cpd -0.006 -0.030 to 0.016
Variance components
σ2
A 174.7 157.5 to 174.4
σ2
C 45.46 30.44 to 62.0
σ2
Cs 43.46 32.88 to 55.26
σ2
E 134.2 131.5 to 136.9
σ2
A.time 0.017 0.003 to 0.044
σ2
C.time 0.031 0.015 to 0.049
σ2
Cs.time 0.064 0.039 to 0.090
σ2
E.time 0.072 0.047 to 0.099
AQuadratic term for age; BCubic term for age; CQuadratic term for weight.
Table 2: Summary of linkage results to change in SBP (SSATR; LOD > 3)
Chromosome Phenotype Marker Location LOD
19 SSATR GATA23B01 33 5.09
4 SSATR GATA7D01 60 4.68
2 SSATR GATA8F07 48 4.67
11 SSATR GGAA5C04 58 4.59
10 SSATR ATA31G11 28 4.26
6 SSATR GGAA15B08 55 4.02
3 SSATR GATA164B08 26 4.00
17 SSATR ATA43A10 89 3.97
Table 3: Summary of linkage results to SBP (SSAR; LOD > 3)
Chromosome Phenotype Marker Location LOD
14 SSAR GATA193A07 96 3.53
8 SSAR GATA72C10 37 3.38
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genome-wide significant [14] linkages were found for
both the SSARs and the SSATRs (Tables 2 and 3). No evi-
dence of genome-wide significant linkage was found for
the simple linear slope. The results suggested that one or
more major loci regulating change in SBP over time may
localize to chromosomes 2, 3, 4, 6, 10, 11, 17, and 19
(Table 2). The results also suggested that one or more
major loci regulating level of SBP may localize to chromo-
somes 3, 8, and 14 (Table 3).
Discussion
Our methods for the analysis of longitudinal data in ped-
igrees have several advantages. They make full use of the
information contained in the repeated observations for
each individual, without first requiring the information to
be summarized in some way. It is simple to include extra
covariates or single-nucleotide polymorphism genotypes
(i.e., association analysis). They allow the inclusion of all
pedigree members, without requiring decomposition of
the pedigrees into smaller structures. These adjusted phe-
notypes can then be usefully used in linkage analyses. The
results obtained suggest that our extended variance com-
ponents models perform well in practice. They are rela-
tively straightforward to fit, and produce useful and
biologically plausible results.
Previous analyses of these data suggested a major locus
regulating longitudinal SBP on chromosome 17
(multipoint LOD = 4.97 at 67 cM) [15]. This finding is
broadly consistent (within 25 cM) of our finding on chro-
mosome 17 for SSATR (multipoint LOD = 3.97 at 89 cM)
(Table 2). Differences in results between this previous
study [15] and our study may relate to differences in phe-
notypic definition (Levy et al. analyzed a residualized lin-
ear slope adjusted for BMI), differences in dealing with
antihypertensive treatment, and differences in the sub-set
of the Framingham Heart Study data analyzed.
Our results support a genetic component to both SBP and
change in SBP with age, and are consistent with a com-
plex, multifactorial susceptibility to the development of
hypertension. The use of SSARs derived from quantitative
traits as input to a conventional linkage analysis has pre-
viously been investigated using both real [11] and simu-
lated data [12], and appears to be valuable in the linkage
analysis of genetically complex traits. An analysis of the
GAW13 simulated data using these methods [6] produced
answers that corresponded well with the simulating
model. We have now demonstrated in this paper the use
of SSARs in the context of longitudinal family data.
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